Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Sep 16, 2013; 1(6): 187-190
Published online Sep 16, 2013. doi: 10.12998/wjcc.v1.i6.187
Published online Sep 16, 2013. doi: 10.12998/wjcc.v1.i6.187
Recurrent epithelial ovarian cancer and hormone therapy
Yoshihito Yokoyama, Hideki Mizunuma, Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8652, Japan
Author contributions: Yokoyama Y and Mizunuma H contributed to this paper.
Supported by The Karoji Memorial Fund of the Hirosaki University Graduate School of Medicine
Correspondence to: Yoshihito Yokoyama, MD, Associate Professor of Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki 036-8652, Japan. yokoyama@cc.hirosaki-u.ac.jp
Telephone: +81-172-395107 Fax: +81-172-376842
Received: April 24, 2013
Revised: May 21, 2013
Accepted: August 4, 2013
Published online: September 16, 2013
Processing time: 140 Days and 0.7 Hours
Revised: May 21, 2013
Accepted: August 4, 2013
Published online: September 16, 2013
Processing time: 140 Days and 0.7 Hours
Core Tip
Core tip: If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.